Remission and time of resolution of nail psoriasis during infliximab therapy Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,

Slides:

Advertisements

Similar presentations

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Advertisements

Kavitha K. Reddy, MD, Jeremy A. Brauer, MD, Roy G. Geronemus, MD

Treatment of folliculitis decalvans with photodynamic therapy: Results in 10 patients Laura Miguel-Gomez, MD, Sergio Vano-Galvan, MD, PhD, Bibiana Perez-Garcia,

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Combined acitretin and Candida antigen versus either agent alone in the treatment of recalcitrant warts Ahmad Nofal, MD, Fathia Khattab, MD, Eman Nofal,

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Clindamycin-induced Sweet syndrome

JAK inhibitors in dermatology: The promise of a new drug class

Reply to: “Nail photography— All 10 fingernails in 1 frame”

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Assessing adherence with phototherapy protocols

Khanh P. Thieu, BS, Harley A. Haynes, MD

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Applying for dermatology residency is difficult and expensive

Kishore L. Jayakumar, BS, Sara S. Samimi, MD

Efficacy of intralesional photodynamic therapy for the treatment of hidradenitis suppurativa Manuel Ángel Rodríguez-Prieto, MD, Luis Miguel Valladares-Narganes,

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Toxic epidermal necrolysis secondary to emergency contraceptive pills

308-nm excimer laser therapy in alopecia areata

Therapy for severe necrotizing vasculitis with infliximab

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Alopecia areata Journal of the American Academy of Dermatology

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition Rosita Saraceno, MD, Graziella Babino,

Stephanie D. Gan, MD, Sarah H

Videodermoscopy of the hyponychium in nail bed psoriasis

Solomon Shockman, MD, Lauren Krug, MD, Nektarios Lountzis, MD

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Pediatric psoriasis treated with apremilast

Pooja H. Rambhia, BA, Ivan J. Stojanov, DMD, Joshua Arbesman, MD

Medicaid acceptance among pediatric dermatologists

Penile calciphylaxis Journal of the American Academy of Dermatology

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Simple onycholysis: A diagnosis of exclusion

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Digital photography in the diagnosis of scabies

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

Treatment of Hailey-Hailey disease with topical calcitriol

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

PUVA therapy in necrobiosis lipoidica diabeticorum

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Remission and time of resolution of nail psoriasis during infliximab therapy Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti, MD, Sergio Chimenti, MD Journal of the American Academy of Dermatology Volume 52, Issue 4, Pages 736-737 (April 2005) DOI: 10.1016/j.jaad.2004.09.012 Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Mean NAPSI variations of group I and II against time. Infliximab induced a progressive clinical improvement of nail psoriasis at the dosage of 5 mg/kg as shown by the statistically significant (P < .0001) reduction of NAPSIm from baseline to week 22. Journal of the American Academy of Dermatology 2005 52, 736-737DOI: (10.1016/j.jaad.2004.09.012) Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Clinical picture of nail psoriasis of fingernails before (a) and after (b) treatment with infliximab at 22 weeks. Journal of the American Academy of Dermatology 2005 52, 736-737DOI: (10.1016/j.jaad.2004.09.012) Copyright © 2005 American Academy of Dermatology, Inc. Terms and Conditions